A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...